Investor profile
Kristen Overly
Private equity, Venture debt & Research and Investments at Royalty Pharma
Kristen Overly is a Research and Investments at Royalty Pharma, whose known portfolio counts 10 companies.
Is Kristen Overly a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- Healthcare
Contacts
Affiliated funds' portfolios
Research and Investments at Royalty Pharma, whose known portfolio counts 10 companies
- Zenas BioPharma
- Zymeworks
- Revolution Medicines
- Elektrofi
- Kailera Therapeutics
- Syndax Pharmaceuticals
- Cytokinetics
- Denali Therapeutics
- Teva Pharmaceuticals
- Ascendis Pharma
Investor Profile
The listing covers sector Healthcare, and focus areas Biotech, Pharma and Pharma Royalties. Startups operating in these areas may find Kristen Overly relevant.
Royalty Pharma appears in Growth, Late-Stage and Series B rounds across its known deals.
The firm portfolio and the focus above give founders context on whether Kristen Overly matches their raise.
Colleagues at Royalty Pharma
Pablo Legorreta
Founder & Chief Executive Officer
New York City, United States
Alim Ladha
Research and Investments
New York, United States
Sam Glazer
Senior Associate, Research & Investments
San Francisco, United States
Volodymyr Nikolenko
Investor
New York, United States
Frequently asked questions
Who is Kristen Overly?
Kristen Overly is a private equity investor and venture debt investor based in New York, United States, listed as Research and Investments at Royalty Pharma. The known portfolio of that firm counts 10 companies. That portfolio belongs to the firm, not to Kristen Overly personally.
What does Kristen Overly invest in?
Listed sectors include Healthcare; listed focus areas include Biotech, Pharma and Pharma Royalties. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Kristen Overly invest at?
Royalty Pharma appears in Growth, Late-Stage and Series B rounds across its known deals, and Kristen Overly is listed there as Research and Investments. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Kristen Overly listed at?
Kristen Overly is listed as Research and Investments at Royalty Pharma. 4 other people in the database share a firm with Kristen Overly.
How do I contact Kristen Overly?
A LinkedIn page is on file for Kristen Overly. It is readable inside RaiseHunt after you create an account. The database holds no email address and no phone number for this profile.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal